News

Laurent Pharmaceuticals Initiates Phase 1 Clinical Study Of “Orphan Drug” Fenretinide in Cystic Fibrosis

Montreal-based biotech startup Laurent Pharmaceuticals Inc. announced Wednesday that the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal has begun enrolling patients in an investigator-initiated clinical trial evaluating the safety, tolerability and pharmacokinetics of a novel oral formulation of Fenretinide in adult subjects with Cystic…

Ataluren Treatment Benefits Some nmCF Patients in Phase 3 Trial from PTC Therapeutics

PTC Therapeutics, Inc. announced unexpected, yet encouraging results of their product ataluren. The biopharmaceutical company focuses on developing small-molecule drugs that target post-transcriptional control processes to alter protein production. Ataluren is PTC’s investigational new drug designed to restore protein function in cystic fibrosis patients with a nonsense mutation (nmCF)…

Cystic Fibrosis Foundation’s Peppermint Oil in Nebulizers Warning Well-Founded, But Teen Researcher’s Findings Merit Further Investigation

Complimentary therapeutic approaches are nothing if not controversial in conventional medicine and mainstream organizations offering information and support for those afflicted with particular diseases. This leaning toward cautious conservatism is commendable, as there is usually plenty of unsubstantiated advice around — often associated with the sale of scientifically unproven…